Pharma Conversation & Community - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Conversation & Community
A round up of news from across the web, including trends from social social media platforms.


Pharmaceutical Technology
Volume 37, Issue 2

HITTING THE HEADLINES

FDA Approvals Increased in 2012



FDA approved 39 new molecular entities and new biologic licenses in 2012, up from 30 in 2011. December is typically an active month for FDA approvals and December 2012 was no exception, with FDA approving seven new drugs.

http://PharmTech.com/Approvals2012/

EMA Reveals Work Program for 2013

The management board of EMA has endorsed the agency's work program for 2013, as well as several activities relating to implementing Europe's new pharmacovigilance legislation. EMA says it expects approximately 100 applications for human medicines in 2013.

http://PharmTech.com/EMA2013/

AbbVie Celebrates Official Launch

AbbVie, a specialty biopharmaceutical company recently spun off from Abbott, was officially launched in January. The new company will employ approximately 21,000 people in more than 40 countries.

http://PharmTech.com/AbbVie/

Partnership Targets Malaria Vaccine R&D

The PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals will be collaborating to advance the development of malaria vaccines using a new vaccine delivery technology that combines genetically engineered DNA with electroporation.

PharmTech/Malaria

INDUSTRY COLLABORATIONS

• A three-year agreement will see Janssen Pharmaceuticals and GlycoVaxyn working together on a multivalent bacterial vaccine.

• Almac and TTP Labtech's alliance will give customers of either party access to a range of biological applications coupled with microplate-reader technology.

• Mobile technology will be used to vaccinate children in Africa against common infectious diseases as part of a collaboration between GlaxoSmithKline and Vodafone.

• OPKO and Bristol-Myers Squibb have expanded their collaboration to identify biomarkers predictive of drug response in several therapeutic areas.

READERS THINK THAT...


View more poll results at: PharmTech.com/Polls

SEEKING INPUT

PharmTech is seeking reader input on process analytical technology and parenterals. Send your questions and thoughts to the editorial team at
.

ON THE BLOG

"From 2013 onwards, we can expect to see more bolt-on acquisitions, more divestitures, and more offshore deals. "

Adeline Siew
http://PharmTech.com/Firepower/

"According to a recently conducted global survey, the overall reputation of the pharma industry declined more in 2012."

Stephanie Sutton
http://PharmTech.com/Reputation/

"With the release of a draft guidance on the evaluation and labeling of abuse-deterrent opioid formulations, FDA is one step closer to clarifying its thinking on acceptable formulations for this product class. "

Amy Ritter
http://PharmTech.com/Opiods/

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here